In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kenya's Kemri begins test kit mass production

This article was originally published in Clinica

Executive Summary

The Kenyan Medical Research Institute, Kemri, has started commercial production of the hepatitis B virus screening kit Kemri HepCell at dedicated new facilities in Nairobi. Kemri has been selling its kits to the ministry of health since 2002, but the decision to begin mass production marks a change in strategy and is designed meet expected growth in demand. It is predicted that Kenya will need around 400,000 HBV tests annually, and Uganda and Tanzania are also showing interest in the product. Currently, imported kits are used to bridge the demand gap not met by the Kemri HepCell kits, which cost around Ksh50 ($0.69), can conduct 200 tests per kit.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts